CN114729060B - 多肽缀合物和使用方法 - Google Patents

多肽缀合物和使用方法 Download PDF

Info

Publication number
CN114729060B
CN114729060B CN202180006277.3A CN202180006277A CN114729060B CN 114729060 B CN114729060 B CN 114729060B CN 202180006277 A CN202180006277 A CN 202180006277A CN 114729060 B CN114729060 B CN 114729060B
Authority
CN
China
Prior art keywords
gln pro
ala gln
gly ala
pro gly
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180006277.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114729060A (zh
Inventor
张媛媛
吴心乐
邹海霞
翟鹏
金耀光
吴博
陈旭
郭威
赵新宇
王作斌
曾伶俐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Zhipeptide Biomedical Technology Co ltd
Original Assignee
Beijing Zhipeptide Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Zhipeptide Biomedical Technology Co ltd filed Critical Beijing Zhipeptide Biomedical Technology Co ltd
Priority to CN202211368599.5A priority Critical patent/CN115925994B/zh
Priority to CN202211370780.XA priority patent/CN115925995A/zh
Publication of CN114729060A publication Critical patent/CN114729060A/zh
Application granted granted Critical
Publication of CN114729060B publication Critical patent/CN114729060B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180006277.3A 2020-09-30 2021-09-30 多肽缀合物和使用方法 Active CN114729060B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211368599.5A CN115925994B (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法
CN202211370780.XA CN115925995A (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020119335 2020-09-30
CNPCT/CN2020/119335 2020-09-30
CN2021099030 2021-06-09
CNPCT/CN2021/099030 2021-06-09
PCT/CN2021/122075 WO2022068920A1 (en) 2020-09-30 2021-09-30 Polypeptide conjugates and methods of uses

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202211370780.XA Division CN115925995A (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法
CN202211368599.5A Division CN115925994B (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法

Publications (2)

Publication Number Publication Date
CN114729060A CN114729060A (zh) 2022-07-08
CN114729060B true CN114729060B (zh) 2022-11-25

Family

ID=80951233

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180006277.3A Active CN114729060B (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法
CN202211370780.XA Pending CN115925995A (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法
CN202211368599.5A Active CN115925994B (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202211370780.XA Pending CN115925995A (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法
CN202211368599.5A Active CN115925994B (zh) 2020-09-30 2021-09-30 多肽缀合物和使用方法

Country Status (7)

Country Link
US (2) US11529394B2 (https=)
EP (1) EP4222176A4 (https=)
JP (1) JP2023545684A (https=)
KR (1) KR20230083294A (https=)
CN (3) CN114729060B (https=)
CA (1) CA3193453A1 (https=)
WO (1) WO2022068920A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729060B (zh) * 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
WO2023179796A1 (en) * 2022-03-25 2023-09-28 Beijing Ql Biopharmaceutical Co., Ltd. Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
WO2023186003A1 (en) * 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
EP4323413A4 (en) * 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
WO2025185605A1 (en) * 2024-03-05 2025-09-12 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
WO2026008836A1 (en) * 2024-07-05 2026-01-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232470A (zh) * 1996-08-30 1999-10-20 诺沃挪第克公司 Glp－1衍生物
CN101712722A (zh) * 2000-12-07 2010-05-26 伊莱利利公司 Glp-1融合蛋白
CN103619175A (zh) * 2011-04-12 2014-03-05 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2016131893A1 (en) * 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998030575A1 (en) 1997-01-08 1998-07-16 Proligo Llc Bioconjugation of macromolecules
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP5275566B2 (ja) 2003-06-18 2013-08-28 ザ スクリプス リサーチ インスティチュート 反応性非天然アミノ酸遺伝コード付加
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
MXPA06006745A (es) 2003-12-18 2006-08-18 Novo Nordisk As Compuestos glp-1 novedosos.
JP2007537142A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ アルブミン様物質に結合した新規のｇｌｐ−１類似物
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
CN101379075B (zh) 2006-02-08 2013-05-15 隆萨股份公司 类胰高血糖素肽的合成
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
EP2444499A3 (en) 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
EP2512518A1 (en) * 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
EA023925B1 (ru) * 2010-04-27 2016-07-29 Зилэнд Фарма А/С Пептидные конъюгаты агонистов рецептора glp-1 и их применение
TW201203798A (en) 2010-07-01 2012-01-16 Tricore Corp Tray sealant filling fixture for spindle motor and the sealant filling method
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN102786590A (zh) * 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
EP2753642B8 (en) 2011-09-06 2017-12-13 Novo Nordisk A/S Glp-1 derivatives
EP2755675B1 (en) 2011-09-12 2018-06-06 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
ES2629735T3 (es) 2012-05-08 2017-08-14 Novo Nordisk A/S Derivados de GLP-1 doblemente acilados
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
KR20150021072A (ko) 2012-06-05 2015-02-27 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 결핍의 치료에 있어서 hgh-xten 융합 단백질 및 이의 용도
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
US20150273069A1 (en) 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
HK1216617A1 (zh) 2013-03-11 2016-11-25 Amunix Operating Inc. 用人生长激素类似物治疗小儿生长激素缺乏症
KR20160021183A (ko) 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
WO2015000942A1 (en) 2013-07-04 2015-01-08 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US10266577B2 (en) * 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
US10689429B2 (en) 2014-04-07 2020-06-23 Novo Nordisk A/S Double-acylated GLP-1 compounds
MX2017006016A (es) 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
JP6983075B2 (ja) * 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3368556B1 (en) * 2015-10-28 2024-04-10 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
AR107560A1 (es) 2016-02-24 2018-05-09 Lilly Co Eli Compuesto que disminuye la glucosa en la sangre
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
EP3463424A1 (en) * 2016-06-02 2019-04-10 Indiana University Research & Technology Corporation Glucagon-like peptide-1-t3 conjugates
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
EP3655427A1 (en) 2017-07-19 2020-05-27 Novo Nordisk A/S Bifunctional compounds
CN110386974B (zh) * 2018-04-19 2022-12-09 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
US11780900B2 (en) * 2018-04-25 2023-10-10 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202028229A (zh) 2018-10-05 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 包含胰島素肽及ｅｇｆ（ａ）肽之雙功能化合物
MX2021012277A (es) 2019-04-11 2021-11-12 Jiangsu Hansoh Pharmaceutical Group Co Ltd Agonista multireceptor y uso medico del mismo.
CN115260313B (zh) * 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN114729060B (zh) * 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232470A (zh) * 1996-08-30 1999-10-20 诺沃挪第克公司 Glp－1衍生物
CN101712722A (zh) * 2000-12-07 2010-05-26 伊莱利利公司 Glp-1融合蛋白
CN103619175A (zh) * 2011-04-12 2014-03-05 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2016131893A1 (en) * 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides

Also Published As

Publication number Publication date
EP4222176A1 (en) 2023-08-09
EP4222176A4 (en) 2024-02-28
JP2023545684A (ja) 2023-10-31
CN115925994A (zh) 2023-04-07
CN114729060A (zh) 2022-07-08
KR20230083294A (ko) 2023-06-09
US20220133856A1 (en) 2022-05-05
US11529394B2 (en) 2022-12-20
CN115925994B (zh) 2023-09-22
CA3193453A1 (en) 2022-04-07
CN115925995A (zh) 2023-04-07
US20240181016A1 (en) 2024-06-06
WO2022068920A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
CN114729060B (zh) 多肽缀合物和使用方法
CN113597434B (zh) Glp-1和gdf15的融合蛋白以及其缀合物
US11510990B2 (en) Conjugates of fusion proteins of GLP-1 and FGF21
US20250276068A1 (en) Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
CN117586423A (zh) 用于代谢病症的融合多肽
US20260000770A1 (en) Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
WO2023186003A1 (en) Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
HK40076645B (en) Polypeptide conjugates and methods of use
HK40076645A (en) Polypeptide conjugates and methods of use
WO2025185605A1 (en) Polypeptide conjugates and methods of uses
HK40099798B (zh) 多肽缀合物的液体药物组合物和其使用方法
HK40099798A (zh) 多肽缀合物的液体药物组合物和其使用方法
JP2026504873A (ja) 融合ポリペプチドの液体医薬組成物およびその使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076645

Country of ref document: HK